Health

#2026-449France eases temporary medicine safety stock rules and sets publication period for small ANSM fines

🇫🇷France··Other·Medium Impact·View source ↗

AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.

🇬🇧 English

France gives the national medicines agency, ANSM, more flexibility to manage drug shortages. For medicines on the official shortage-risk list, the agency can temporarily lower required safety stock levels when there is force majeure, an objectively justified exceptional situation, or a need to cover the shortage of a therapeutic alternative. The change affects pharmaceutical companies and marketing authorization holders that must keep safety stocks. Any reduction can last up to six months and can be renewed if the problem continues. The decree also says small ANSM financial sanctions below €10,000 will stay published on the agency’s website for six months.

AI-generated summary. May contain errors. Refer to official sources for legal decisions.

Key Changes

  • Allows ANSM to temporarily lower safety stock requirements for shortage-risk medicines in defined exceptional situations
  • Limits each stock-threshold reduction to six months, with renewal possible if the situation continues
  • Sets a six-month online publication period for ANSM financial sanctions below €10,000

Obligations

What this law requires

medium

Marketing authorization holders and pharmaceutical companies exploiting medicines on the official shortage-risk list may request a temporary reduction of the required safety-stock threshold only where the request is justified by force majeure, an objectively justified exceptional situation, or the need to address a shortage of a therapeutic alternative.

marketing authorization holderspharmaceutical companies exploiting shortage-risk medicines
ANSM silence for more than two months after submission is deemed a rejection
operational
medium

When ANSM grants a reduction of the required safety-stock threshold for a shortage-risk medicine, the reduced threshold applies only temporarily for a maximum period of six months, renewable if the underlying situation persists.

marketing authorization holderspharmaceutical companies exploiting shortage-risk medicines
Maximum six months per decision, renewable if the situation persists
operational
low

ANSM must keep financial sanction decisions imposed under Article L. 5423-9 for amounts below €10,000 available on its website for six months from their publication date.

French National Agency for the Safety of Medicines and Health Products
Six months from the date of publication
disclosure

Affected Parties

Pharmaceutical companiesMarketing authorization holders+2 more…

Tags

medicine shortages,pharmaceutical supply,ANSM